News & Updates

Melflufen for R/R MM: Yay or nay?

06 May 2022 by

In patients with relapsed/refractory multiple myeloma (R/R MM), a combination of melflufen and dexamethasone proved better than an approved doublet standard-of-care (SoC) comprising pomalidomide-dexamethasone in terms of progression-free survival (PFS), the phase III OCEAN trial has shown. However, the overall survival (OS) outcome with the melflufen-containing regimen appeared to digress from the PFS result, potentially casting doubt on its benefit for this condition.

Melflufen for R/R MM: Yay or nay?

06 May 2022

Corporotomy site of no safety consequence in IPP implantation

06 May 2022 by

The location of corporotomy during the implantation of inflatable penile prostheses (IPP) does not seem to affect the incidence intraoperative or short-term postoperative complication, according to a recent study.

Corporotomy site of no safety consequence in IPP implantation

06 May 2022

Add-on favipiravir brightens outlook for hospitalized COVID-19 patients

06 May 2022

When used in addition to standard of care, favipiravir leads to faster viral clearance and clinical improvement time among patients hospitalized with COVID-19, although it appears to contribute to an increased risk of hyperuricaemia, according to the results of a meta-analysis

Add-on favipiravir brightens outlook for hospitalized COVID-19 patients

06 May 2022

Residential noise can take toll on mental health

06 May 2022

Exposure to noise, particularly in residential areas, appears to have negative consequences on mental health, as reported in a study.

Residential noise can take toll on mental health

06 May 2022

Adebrelimab plus chemo almost doubles OS, triples PFS in extensive-stage SCLC

06 May 2022 by

Adding adebrelimab to chemotherapy improves survival outcomes over chemotherapy alone in patients with extensive-stage small cell lung cancer (SCLC) in the phase III CAPSTONE-1 study presented at AACR 2022. This brings hope to SCLC patients with limited treatment options and poor prognoses.

Adebrelimab plus chemo almost doubles OS, triples PFS in extensive-stage SCLC

06 May 2022

Open surgery a better option than minimally invasive hysterectomy in early cervical cancer?

05 May 2022 by

Undergoing a minimally invasive radical hysterectomy leads to worse survival outcomes compared with open surgery in patients with early cervical cancer, according to final results of the LACC trial presented at SGO 2022.

Open surgery a better option than minimally invasive hysterectomy in early cervical cancer?

05 May 2022

UWFA detects more retinal capillary nonperfusion in temporal quadrant

05 May 2022

Ultra-widefield angiography (UWFA) is able to identify more retinal capillary nonperfusion (RCNP) than conventional fundus fluorescein angiography, particularly in the temporal quadrant. Of note, large increases in RCNP over 100 weeks of follow-up seeme to be uncommon.

UWFA detects more retinal capillary nonperfusion in temporal quadrant

05 May 2022

Adding durvalumab upfront to chemo ups long-term survival in SCLC

05 May 2022 by

Patients were threefold more likely to survive long term (beyond 3 years) when durvalumab was added to first-line chemotherapy, with or without tremelimumab, compared with those on chemotherapy alone, according to a post hoc analysis of long-term survivors (LTS) with extensive-stage small-cell lung cancer (ES-SCLC) in the CASPIAN study.